IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America
- Appointment of experienced healthcare executive Shad Good as VP of Sales for North America
- Good's extensive experience in medical device sales and leadership
- Good's knowledge of minimally invasive breast diagnostics and therapeutic systems
- Good's proven track record in exceeding sales expectations
- None.
- Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as
U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systems - Immediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024
Mr. Good, a proven and results-oriented executive, has worked with global market leaders as well as high-growth medium sized businesses. He was most recently VP of Sales at UV Concepts Inc. Prior, he served as Senior Director of Sales,
"Having worked in medical device sales and specifically with minimally invasive breast diagnostics and therapeutic systems, I'm excited to be joining IceCure and to lead its sales campaign for the ProSense System in the
IceCure's Chief Executive Officer, Eyal Shamir, commented, "Our review and recruitment process was extensive given the importance of this newly-created position at this juncture. I believe Shad is the right person for this very important position. It is with great confidence and belief in his indication-specific knowledge, skills, network, and proven sales leadership track record that we have appointed him to lead ProSense's sales in
About IceCure Medical
IceCure (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward looking Statements
This press release contains forward looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal and Israeli securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward looking statements. For example, IceCure is using forward looking statement in this press release when it discusses the responsibilities of Mr. Good under his new role, including to build out the sales infrastructure in anticipation broader commercialization of ProSense in the
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kerhli
Phone: 310-625-4462
Logo : https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
SOURCE IceCure Medical